Chengxin Luo

509 citations
23 papers · 363 indexed · h-index 10
Topics
Hematopoietic Stem Cell Transplantation (9 papers)Acute Myeloid Leukemia Research (5 papers)Lymphoma Diagnosis and Treatment (4 papers)

In The Last Decade

Chengxin Luo

22 papers receiving 353 citations

Peers

Chengxin Luo
Comparison fields: 5 of 72
  • Molecular Biology 119
  • Oncology 98
  • Immunology 89
  • Genetics 76
  • Hematology 61
Replace Geom-Seog Seo with:
Geom-Seog Seo South Korea
Kory J. Engelke United States
S. D’Alò Italy
Shailaja Sopory India
Daiana Giannini Italy
Jeanette Osban United States
Susanne Aschermann Germany
Tatiana Abramova United States
Shiori Shikata Japan
Carmen Coxon United Kingdom
Chengxin Luo relative to Geom-Seog Seo South Korea Geom-Seog Seo's profile →
Citations per field
00.5×3.8×
Geom-Seog Seo · 1×
Citations per year

Countries citing papers authored by Chengxin Luo

Since Specialization
Citations

This map shows the geographic impact of Chengxin Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengxin Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengxin Luo more than expected).

Fields of papers citing papers by Chengxin Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengxin Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengxin Luo. The network helps show where Chengxin Luo may publish in the future.

Co-authorship network of co-authors of Chengxin Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Chengxin Luo. A scholar is included among the top collaborators of Chengxin Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengxin Luo. Chengxin Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 4
4 6
5 2
6 11
7 3
8 40
9 9
10 32
11 5
12 9
13 4
14 2
15 14
16 17
17 35
18 12
19
Upregulation of the transient receptor potential vanilloid 1 in colonic epithelium of patients with active inflammatory bowel disease.
25
20 120

About Chengxin Luo

Chengxin Luo is a scholar working on Hematology, Oncology and Transplantation, having authored 23 papers that have together received 363 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (9 papers), Acute Myeloid Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). The work is most often cited by research in Hematology (61 citations), Immunology (89 citations) and Genetics (44 citations). Chengxin Luo has collaborated with scholars based in China, United States and Pakistan. Frequent co-authors include Hu Zhang, Zhen Yu, Shuangnian Xu, Zhu‐Jun Wang, Xi Li, Jieping Chen, Guixian Wu, Min Zhu, Yanni Ma and Zhen Huang. Their work appears in journals such as Blood, Scientific Reports and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026